We aim to give a comprehensive review, updated to 2002, of the most important and representative molecular genetic studies, performed mainly within the past decade, that aimed to identify the gene(s) involved in osteoporosis. Early reviews were largely confined to association studies in humans, but we review here, separately, the results of both association and linkage studies in humans, and quantitative trait locus (QTL) mapping in animal models. The main results of all the studies are tabulated for comparison and ease of reference, and to provide a comprehensive retrospective view of molecular genetics studies of osteoporosis. The most striking findings and the most representative studies are singled out for comment regarding the immediacy of their influence on present understanding of the genetics of osteoporosis and on the current status of genetic research in osteoporosis. This is particularly relevant for studies on the association of the vitamin D receptor (VDR) gene, for which there has been a large body of studies and reviews published. The format adopted by this review should be ideal for accommodating future new advances and studies in a fairly young field that is still developing rapidly.
Introduction
The genetics of osteoporosis represents one of the most active areas for research in bone biology. With many new publications emerging each year, the field of osteoporosis genetics research has a pressing need for periodical reviews lending an up-to-date and objective retrospective analysis and overview on both the methodologies for, and the discoveries made as a result of, the endeavours to identify the genetic factors and gene-environment interactions underlying osteoporosis. A few review articles are available that address the role of genetic factors in osteoporosis (Audi et al. 1999 , Eisman 1999 , Zmuda et al. 1999a , Stewart & Ralston 2000 , Rizzoli et al. 2001 , Peacock et al. 2002b , Ralston 2002 ) and strategies for the search for osteoporosis genes , Blank 2001 . Recently, reviewed the current methodologies of gene mapping for osteoporosis on the basis of their experience with molecular genetics in relation to bone, and the use of statistical genetics in the identification of genes for complex traits. As a complement to that, the present review offers a comprehensive overview of the important findings made within the past decade in the field of genetics of osteoporosis. The results of important studies are entered in Tables for the purpose of comparison and ease of reference. Table 1 summarizes the major candidate genes subject to association studies. Tables 2 and 3 include association studies that produced positive and negative results respectively. Table 4 summarizes studies on risk prediction with genetic factors for osteoporosis and other related diseases. Table 5 highlights the studies on geneby-gene or gene-by-non-genetic factor interactions. Given that, currently, there is no detailed review dedicated to studies using the approaches of linkage analysis in humans and quantitative trait locus (QTL) mapping in animal models in osteoporosis research, these studies are elaborated upon and summarized individually in this article in Tables 6, 7, 9 and 10 respectively. The issue regarding the statistical power of the current linkage analysis is summarized in Table 8 and Fig. 1 .
Comments are made on the most representative findings for their immediate influence on the understanding of the genetic basis of osteoporosis and on current trends in genetic research in osteoporosis. This is particularly relevant for association studies of the vitamin D receptor (VDR) gene, on which numerous studies have been published and several other in-depth review articles are available (Ferrari et al. 1998c , Eisman 1999 , Stewart & Ralston 2000 , Rizzoli et al. 2001 , Peacock et al. 2002b , Ralston 2002 .
Association studies
The genetic study of osteoporosis has been based largely on research into candidate genes relevant to bone metabolism (Table 1) . The VDR gene, the collagen type I 1 (COLIA1) gene, and the estrogen receptor-(ER-) gene are among those most intensively studied.
VDR gene
Polymorphisms at four marker loci within the VDR gene have been identified as related to biological variations in bone mass. All these polymorphisms are restriction fragment length polymorphisms (RFLPs). Recently, a novel polymorphism in the binding site for Cdx-2 (an intestinespecific homeodomain-containing transcription factor) in the VDR gene promoter region was also associated with variation in bone mineral density (BMD) in a Japanese population (Arai et al. 2001) .
The association of the VDR gene polymorphism with bone turnover was first revealed in a study of 91 individuals of white British-Australian origin (Morrison et al. 1992) . In that study, the VDR gene polymorphism was predictive of circulating osteocalcin concentrations, such that the concentrations of osteocalcin in BB individuals of the BsmI polymorphism were significantly greater than those in bb individuals. Similar effects were also found for the ApaI and the EcoRV RFLPs. The result was complemented by a subsequent study (Morrison et al. 1994 ) that identified the relationship of the BsmI polymorphism of the VDR gene to bone density variation -namely, that Ogata et al. 2001 individuals with the bb genotype had significantly greater bone density than others. Differences in bone density predicted by this association accounted for up to 75% of the total genetic effect on bone density in normal individuals. Although these findings were overestimated as a result of genotyping errors (Morrison et al. 1997) , they stimulated a host of studies on the effects of VDR gene polymorphisms on bone-related traits in a variety of populations (Table 2 ) and sparked a new era of research into the identification of genes for osteoporosis. After the study by Morrison et al. (1992) , several association studies in white populations confirmed the influence of the VDR gene polymorphism on variation in BMD (Table 2) . In a population of 470 premenopausal women, spinal and trochanter BMD were significantly correlated with BsmI polymorphism (Salamone et al. 1996) . Association with BMD was also detected for polymorphisms at other marker loci of the VDR gene, such as the TaqI (Spector et al. 1995) and FokI (Gross et al. 1996) polymorphisms. The association even held good for different races, as demonstrated by a study in 202 premenopausal Japanese women (Tokita et al. 1996) .
A series of studies aimed to unravel the underlying mechanisms of the effects of the VDR gene on bone metabolism that lead to the eventual variation in bone phenotype. Association studies in which relevant bone biochemical markers were used as surrogate phenotypes have illustrated the VDR gene polymorphism in various aspects of bone metabolism. Studies of the concentrations of markers of bone turnover revealed that the state of bone turnover differed across VDR genotypes (Morrison et al. 1992 , Tokita et al. 1996 , Lorentzon et al. 2001 , Sheehan et al. 2001 . In the study by Tokita et al. (1996) , the Bb genotype was associated with a state of both greater bone turnover and lower BMD values than its counterpart bb, supporting the concept that the regulatory effect of the VDR gene on bone and mineral metabolism leads to variation in bone mass as the end-point phenotype.
The influence of VDR gene polymorphism on Ca 2+ homeostasis has also been extensively studied. In 72 healthy children, the FokI polymorphism was related to calcium absorption (Ames et al. 1999 ). The FF individuals had both greater mean calcium absorption and greater BMD values than did Ff and ff individuals. This may suggest a differential action of the VDR alleles on intestinal calcium absorption, which in turn leads to the different degrees of accrual of BMD in these children. Such variation in calcium absorption was further defined in a study of 60 postmenopausal women (Dawson-Hughes et al. 1995) . When calcium intake was limited, a lower fractional calcium absorption occurred in BB individuals compared with bb individuals. This inefficient calcium absorption in the BB genotype is a reflection of functional variation in the intestine VDR that may be determined by the VDR gene polymorphism. The modulation of intestinal calcium absorption by VDR polymorphism was confirmed in a group of postmenopausal Thai women (Ongphiphadhanakul et al. 1997) and in two independent studies on the ApaI and TaqI polymorphisms (Gennari et al. 1997 , Wishart et al. 1997 .
A more comprehensive view of the influence of the VDR gene on bone homeostasis was achieved in a study of 21 premenopausal women (Howard et al. 1995) . The BB genotype, in comparison with the bb genotype, had a greater set point for feedback inhibition of parathyroid hormone (PTH) initiated by an increase in 1,25-dihydroxyvitamin D (1,25-(OH) 2 D), more active bone resorption and breakdown of type I collagen, and greater concentrations of 1,25-(OH) 2 D required to maintain normocalcemia. These findings indicate possible differences between VDR genotypes with respect to the quality or quantity of VDRs in different target tissues (DawsonHughes et al. 1995 , Ongphiphadhanakul et al. 1997 .
A dynamic picture of bone growth was provided by studies on variations, not only in childhood bone accrual and adolescent peak BMD, but also in age-related bone loss. In a study on prepubertal girls, the AA genotype of the ApaI polymorphism and the BB genotype of the BsmI polymorphism were associated with lower BMDs than were found in the aa and bb individuals (Sainz et al. 1997) . Such a difference in BMD between the BsmI genotypes might persist through adolescence, given the findings of another study of 75 young Finns, among whom those with the genotype bb had significantly greater peak bone mass than did those with the BB genotype (Viitanen et al. 1996) . Peak bone mass was also found to be correlated with the ApaI, BsmI and TaqI polymorphisms in 677 white women, although in this case the BB rather than the bb individuals had the greatest peak bone mass (Rubin et al. 1999) . Similarly, age-related bone loss differs between the VDR BsmI genotypes. In a group of elderly individuals, Ferrari et al. (1995) found that those with the BB genotype lost bone, whereas no significant bone loss was suffered by the bb individuals. Such a trend of association was also detected in a population sample of larger size (Brown et al. 2001) , in whom the individuals TT for the TaqI polymorphism had lower rate of bone loss than those with other genotypes. Given the tight linkage disequilibrium of the b allele with the T allele, the bb individuals might also be those with less bone loss. The TT and bb genotypes were associated with less bone loss in two other independent studies, one in patients with early rheumatoid arthritis and another in postmenopausal Japanese women (Gough et al. 1998 , Kikuchi et al. 1999 .
A tentative conclusion that can be made on the basis of the data summarized so far in this text is that the bb or TT genotypes of the VDR gene are more advantageous in terms of bone metabolism, calcium homeostasis, bone accrual during childhood and bone 'retention' later in life. Conversely, BB or tt individuals might be those more likely to develop osteoporosis. With progressively expanding new data, such a contention may not always hold, as 
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was the case in the study by Uitterlinden et al. (2001) and in situations in which disease, nutrition and environmental factors have an important influence on bone metabolism (Rubin et al. 1999) . Studies on VDR gene polymorphism have also been extended to clinical settings, including hormone replacement therapy (HRT) or calcium supplementation.
A study in 328 elderly white individuals demonstrated that an increase in BMD in response to calcium intake was present only in those with the bb polymorphism (Kiel et al. 1997) . However, this advantage for bb individuals could be translated to significantly greater BMD values only if calcium intake exceeded a certain threshold, as suggested by the study in which BMD was greater for bb than for BB or Bb genotypes only in a group in whom calcium intake was greater than 800 mg/day. The opposite genetic effect was found in a sample of prepubertal girls (Ferrari et al. 1998a) : with increasing dietary calcium intake, BMD accrual increased in only the Bb, and possibly the BB, girls; those with the bb genotype, although having the greatest baseline BMD accrual, remained unaffected, suggesting that high-dosage calcium intake may mask differences in BMD among VDR genotypes during the prepubertal period. Given the findings of these two studies, it is possible that the efficiency of calcium absorption declines with age more significantly in individuals of BB genotype than in those with the bb genotype, making the elderly BB individuals become less responsive to calcium supplementation. A lower fractional absorption of Ca 2+ in BB than in bb individuals had previously been observed in a study of 60 postmenopausal women (Dawson-Hughes et al. 1995) .
In a study similar to those on calcium supplementation, the effect of vitamin D supplementation on BMD was also tested for its relationship with VDR gene polymorphism. Two studies on the increase in BMD in response to vitamin D supplements, one in a Japanese population and another in a Dutch population, identified a positive association of a therapeutic effect of vitamin D with certain VDR genotypes (Matsuyama et al. 1995 , Graafmans et al. 1997 . The bb genotype was associated with a greater increase in BMD in the Japanese, but the opposite effect was found in the Dutch population, possibly resulting from allelic heterogeneity of the BsmI locus or from different environments for the Japanese and the Dutch populations.
The effect of HRT and bisphosphonate treatment in terms of BMD gain also differs between the VDR genotypes. A study in Japanese women receiving HRT for more than 1 year identified different percentage increases in BMD between TaqI genotypes (Kurabayashi et al. 1999) . The TT genotype benefited from HRT more than did the Tt, with not only a greater increase in BMD, but also a significant decrease in the concentrations of markers of bone resorption. The response to bisphosphonate treatment in combination with calcium supplementation was also found to be modified by the VDR genotype in postmenopausal women with osteoporosis (Marc et al. 1999) . The lumbar spine BMD increased more rapidly in BB and Bb groups than in the bb group during the 1-year period of treatment, with the bb individuals exhibiting the greatest decrease in osteocalcin concentrations.
Studies on the VDR gene polymorphism have been fraught with conflicting results (Table 3 ). Many welldesigned studies could not replicate the allelic associations of the VDR gene with bone variables identified in other studies. In the study performed on the largest sample so far (Uitterlinden et al. 1996) , the polymorphisms for the marker loci of BsmI, ApaI, and TaqI failed to associate with BMD individually. The only positive association, although weak, was found for the haplotype 'bAT', with lower BMD in the femoral neck. Another large-scale association study (Jorgensen et al. 1996) also could not establish a relationship between the VDR genotypes and BMD at the lumbar spine, hip and forearm or with postmenopausal bone loss. Even among the studies with positive findings, contradictory results exist regarding the effects of the VDR alleles on phenotypes. For example, whereas most studies found that the b allele or the bb genotype was associated with greater BMD (Morrison et al. 1994 , Krall et al. 1995 , some studies have indicated the opposite (Houston et al. 1996 , Salamone et al. 1996 .
One explanation for the negative findings surrounding the study of the VDR gene polymorphism (Table 3 ) may lie in the interaction between gene and environment. Because of the polygenic nature of osteoporosis and bone mass determination, VDR polymorphism may underlie only a modest component of the total variation of bonerelated traits. As a result, the effect of the polymorphism is often masked by environmental factors. A study by Kiel et al. (1997) found that the association of BsmI polymorphism with BMD existed only in a group with a calcium intake of more than 800 mg/day. Similarly, another study on TaqI polymorphism showed that the marker's association with BMD was most significant when daily calcium intake exceeded 684 mg (Rubin et al. 1999) . Two other studies indicated that the correlation of the VDR gene polymorphism with BMD tended to disappear with age and might exist only in the premenopausal (Riggs et al. 1995) or even the prepubertal period (Ferrari et al. 1998a) .
As for the different directions of the genetic effect detected by various studies (i.e. which allele is associated with low or high BMD), either linkage disequilibrium of the VDR polymorphic markers with genes related to bone metabolism, or allelic heterogeneity at a certain VDR locus for different populations may account for the discrepancies. Theoretically, a recombination between a VDR locus and a gene related to bone metabolism, which does not occur in other populations, can lead to a positive association with an opposite effect. Allelic heterogeneity, manifested by different alleles having the same effect (or the same allele having different effects) for different populations, could arise from gene-environment interactions, as the same allele may function differently in different environments. Apart from the above situations, population admixture is another important factor potentially leading to conflicting results in VDR association studies (Deng 2001) . Population admixture may result in false-positive identification of the association of a polymorphism with a complex trait (Chakraborty & Smouse 1988 , Deng & Chen 2000b , Deng et al. 2001a . It could also mask, change or reverse true genetic effects of genes underlying complex traits, as demonstrated by Deng (2001) through a simple one-locus population genetics model.
The VDR gene maps to chromosome 12q13-14 and contains at least 11 exons (Haussler et al. 1998) . The BsmI polymorphism is located between exon VIII and the 3 non-coding region. The TaqI restriction site, defining the TaqI polymorphism, is located within exon IX. Between these two polymorphisms within intron VIII is the ApaI polymorphic locus. A strong linkage disequlibrium exists between the BsmI and TaqI polymorphism such that the B allele is usually associated with the t allele and the BB genotype is almost equivalent to the tt genotype. In contrast, the ApaI RFLP is not strongly associated with the BsmI and TaqI RFLPs. In addition to the three loci, another polymorphism, the start codon polymorphism (SCP), as identified by the FokI polymorphism, is located at the translation initiation site in exon II. Unlike the first three polymorphisms, which do not result in amino acid changes, the SCP causes a change in VDR structure, making the F allele VDR three amino acids shorter than those of the f allele. Such a difference in VDR primary structure could lead to altered receptor function (Arai et al. 1997) .
Although the BsmI locus is intronic, a number of mechanisms have been invoked to explain how this polymorphism might influence expression of the VDR gene and alter BMD. One mechanism is disruption of a splice site for VDR mRNA transcription. Another mechanism involves changes in mRNA stability or in the intronic regulation element (Cheng et al. 1994 , Nesic et al. 1993 . As suggested by Morrison et al. (1994) , the B allele was associated with greater levels of VDR through enhanced transcriptional activity or greater mRNA stability. However, the difference either in VDR mRNA stability or in VDR mRNA levels between VDR genotypes/alleles could not be detected in other studies (Mocharla et al. 1997 , Verbeek et al. 1997 . Attempts to relate VDR genotype with VDR concentrations in duodenal mucosa also failed (Barger-Lux et al. 1995) . To explore further the effects of BsmI polymorphism on the properties of the VDR and on cellular responsiveness to 1,25(OH) 2 D 3 , a study was conducted on cultured skin fibroblasts from BB, Bb and bb individuals (Gross et al. 1998a) . Among the three genotypes, no significant differences were found in VDR abundance, affinity for [ 3 H]1,25(OH) 2 D 3 , VDR mRNA levels and fibroblast responsiveness to 1,25(OH) 2 D 3 . Given the above findings, it is unlikely that the VDR BsmI (or TaqI) polymorphism is functionally related to variation in BMD; rather, it may be only a marker in strong linkage disequilibrium with a nearby functional mutation that underlies variations in bone mass. Other possibilities remain open to investigation; for example, functional variations in the VDR that are caused by the BsmI polymorphism might be detectable only in specific tissues, such as bone or intestine.
As the SCP (the FokI RFLP) leads to production of VDR proteins that differ in length by 3 amino acids, the polymorphism may represent a mechanism resulting in variation in BMD. Using transfected HeLa cells, Arai et al. (1997) detected significantly greater vitamin D-dependent transcriptional activation for the F allele (short type) VDR than for the f allele (long type) VDR. However, another study on the two types of VDR expressed in COS-7 cells failed to confirm a functional relevance of the FokI SCP. There was no difference detected between the two isoforms of the VDR with respect to affinity for [ 3 H]1,25(OH)D 3 , ability to bind DNA and ability to transactivate target genes (Gross et al. 1998b) . Moreover, in human fibroblasts of the three genotypes -FF, Ff and ff -the sensitivity to 1,25(OH) 2 D 3 with respect to the induction of 24-hydroxylase mRNA was also generally the same (Gross et al. 1998b ). The above findings should be interpreted with caution. Current approaches to the detection of small differences in VDR transactivation activity are limited by low sensitivity; as a result, physiologically important but small functional differences between the F and f VDR isoforms could be undetected. In addition, differential function caused by the FokI SCP may manifest itself only in some specific tissues, such as bone and intestine. Conversely, the lack of functional significance of the FokI SCP of the VDR gene, as indicated in the study by Gross et al. (1998b) , supports the hypothesis that this polymorphism, as in the case of the BsmI polymorphism, could be only a marker in linkage disequilibrum with a nearby gene that is functionally related to bone mass regulation.
Recently, a novel polymorphism in the Cdx-2 binding site of the VDR gene promoter region was identified (Yamamoto et al. 1999 , Arai et al. 2001 . The polymorphism was defined by an A<G change at the 3731nt relative to the transcription start site of the VDR gene. Functional analysis of the polymorphic region, which is also called the human VDR-sucrase-isomaltase footprint 1 (hVD-SIF1) sequence, was performed using an intestinal cell line as a model system (Yamamoto et al. 1999) . It was found that, by binding to the hVD-SIF1 sequence, Cdx-2 was able to activate VDR gene transcription. Mutations of the sequence suppressed transactivation activity. Insertion of a fragment containing the hVD-SIF1 sequence upstream of the thymidine kinase promoter of a herpes simplex virus enhanced its transcription activity. These findings suggest the important role of the Cdx-2 binding site in regulation of intestine-specific VDR gene expression.
To test the significance of the Cdx polymorphism in human population, an association study was conducted in 261 Japanese women (Arai et al. 2001) . The BMD at the lumbar spine of the Cdx-A homozygotes was significantly greater than that in the Cdx-G homozygotes. Functional analysis of the two genotypes showed markedly decreased transcriptional and Cdx-2 binding activities for the Cdx-G homozygotes as compared with the Cdx-A homozygotes. Given the close relationship between the Cdx polymorphism and the intestinal expression of the VDR, it is speculated that the polymorphism regulates BMD through intestinal VDR content, an important factor contributing to the development of osteoporosis. As estrogen was able to upregulate the expression of VDR in the duodenal mucosa (Liel et al. 1999) , the effect of the Cdx polymorphism on BMD may be influenced by estrogen status, as indicated by the finding of the association of the Cdx polymorphism with BMD only in postmenopausal, and not premenopausal, women (Arai et al. 2001) . The significance of the polymorphism for bone has yet to be validated. A more recent study in a group of Korean women was unable to replicate the association of the Cdx polymorphism with BMD (Kim et al. 2002b ). Furthermore, the study failed to detect a significant difference in prevalence of the polymorphism between patients with osteoporosis and normal controls.
COLIA1 gene
Mutations in the COLIA1 gene cause osteogenesis imperfecta, a disease characterized by moderate to severe bone fragility (Byers 1990 ). The similar bone brittleness observed in osteogenesis imperfecta and in osteoporosis makes it interesting to speculate that osteoporosis may also be caused by mutations of the COLIA1 gene. Screening the transcriptional control regions of the COLIA1 gene identified a G<T substitution at the first base of a consensus site in the first intron for the transcriptional factor, Sp1 (Chu et al. 1985 , Rossouw et al. 1987 . The polymorphism was thus named the Sp1 polymorphism. A population-based study of this polymorphism detected an association with BMD in two groups of British women (Grant et al. 1996) : BMD was greater for the G/G (SS) genotype than for the G/T (Ss) and T/T (ss) genotypes. Over-representation of the unfavorable Ss and ss genotypes was found in patients with osteoporosis and fractures, conferring a relative risk of 2·97 for vertebral fracture in individuals carrying the s allele.
Functional analysis of the Sp1 polymorphism by Mann et al. (2001) demonstrated functional differences between the two alleles. The s allele had greater affinity for Sp1 protein than did the S allele. In the Ss heterozygotes, the RNA transcripts derived from the s allele were three times more abundant than those from the S allele, suggesting allele-specific transcription or a different splicing process for the two alleles. Increased ratios of 1(I) to 2(I) protein in collagen and increased ratio of COLIA1 to COLIA2 mRNA were detected using osteoblasts cultured from the Ss heterozygotes. This is consistent with the possibility of an increased production of 1(I) 3 , which was reported by several investigators to be responsible for impaired bone strength in osteogenesis imperfecta (Deak et al. 1985 , Chipman et al. 1993 , Saban et al. 1996 , McBride et al. 1998 . Although the presence of 1(I) 3 could not be determined, in individuals carrying the s allele the study did reveal a decrease in bone strength that was independent of BMD, suggesting that decreased bone strength may be caused more by poor organic (e.g. collagen) content of bone than by decreased bone mineral content.
The positive association of the Sp1 polymorphism with bone phenotypes has been confirmed in several studies. Two large-scale studies identified the relationship of the Sp1 genotype with BMD in 1778 postmenopausal Dutch women and in 715 peri-and postmenopausal Italian women (Uitterlinden et al. 1998 , Braga et al. 2000 , with BMD difference between the Sp1 genotypes becoming more significant with increasing age in the first study. The association with BMD has also been identified in prepubertal girls (Sainz et al. 1999) and elderly men ( VanPottelbergh et al. 2001a ). The Sp1 polymorphism may also influence bone loss and bone turnover, with the ss genotype associated with greater bone loss (Harris et al. 2000 , MacDonald et al. 2001 and increased levels of bone turnover (Keen et al. 1999) . Notably, the association with bone loss could be modulated by dietary calcium intake, as was reported by Brown et al. (2001) , who found that lumbar spine bone loss was greater in the ss and Ss genotypes than in the SS genotype for the lowest tertile of calcium intake, but that the opposite effect (i.e. SS individuals lost more bone than the Ss and the ss individuals) was true for the greatest calcium intake. The Sp1 polymorphism has been found to be associated with response to bisphosphonate treatment in postmenopausal women with osteopenia (Qureshi et al. 2002) . However, the association was significant only at the femoral neck, suggesting a site-specific effect of the polymorphism. Over-representation of the s allele or the ss genotype in patients with osteoporosis or fractures has been reported in many studies (Table 4) . The s allele or ss genotype confers a risk for osteoporosis or fractures with an odds ratio ranging from 2·1 (Weichetova et al. 2000 , Mezquita-Raya et al. 2002 to 11·83 (Langdahl et al. 1998) . The relevance of the polymorphism to risk of fracture could probably be mediated through variations in bone geometry, as indicated by the findings of a recent study in which the femoral neck-shaft angle was wider in Ss/ss than in the SS individuals, which led to a greater risk of fracture for the former group (Qureshi et al. 2001) .
Two new single nucleotide polymorphisms (SNPs), 1663 indelT and 1997 G/T, were identified within the COLIA1 promoter region (Garcia-Giralt et al. 2002) . When tested in 256 postmenopausal women, the 1997 G/T SNP showed association with BMD at the lumbar spine and femoral neck. There was no association with BMD for the 1663 indelT SNP, but the marker was in strong linkage disequilibrium with the Sp1 polymorphism, suggesting that the two polymorphisms may be functionally related to each other. Functional assays found that the regions containing these two SNPs may be the binding sites of primary osteoblast nuclear proteins. There might be interactions of the two SNPs with the Sp1 polymorphism, because individuals heterozygous at all of the three loci had the greatest BMD. Further studies are necessary to delineate the mechanisms underlying the effects of these SNPs on BMD variation and to test their clinical relevance for general populations. Association studies of the COLIA1 gene have also been inconsistent, as in the case of the VDR gene polymorphisms (Table 3) . A series of studies could not establish an association of the Sp1 polymorphism with BMD (Aerssens et al. 1998 , Sowers et al. 1999 , Berg et al. 2000 , Ashford et al. 2001 , bone turnover (Sowers et al. 1999 , Aerssens et al. 2000 , Heegaard et al. 2000 , bone loss (Heegaard et al. 2000) , bone accrual (Berg et al. 2000) and other bone phenotypes, such as calcaneal broadband ultrasound attenuation (Ashford et al. 2001) . Furthermore, one of these studies (Aerssens et al. 1998) failed to detect differences in genotype prevalence between osteoporotic patients and control groups.
In an attempt to clarify the inconsistencies, two metaanalyses were conducted. The first was performed using the data from 16 studies published between October 1996 and October 2000 (Mann et al. 2001) . According to the meta-analysis, there is a significant association between possession of the COLIA1 s allele and low BMD, with a clear allele dose-effect at both the lumbar spine and femoral neck. This association was also found to be independent of body mass index (BMI). Another metaanalysis was conducted on data from 13 studies with 3641 participants (Efstathiadou et al. 2001b) . A dose-response relationship of the Sp1 polymorphism with fracture prevalence was identified. It was also found that the effect of the polymorphism was greater for vertebral fractures and tended to disappear when the individual was older than 65 years.
Results from these two meta-analyses, together with the data from functional studies (Mann et al. 2001) , confirmed the importance of the Sp1 polymorphism in bone metabolism. An investigation of the polymorphism on ethnically different samples estimated that from 1·7% to 6·8% of the difference in hip fracture rates between Asian and white polulations may be attributed to difference in prevalence of the s allele between the two populations (Beavan et al. 1998) . However, because of the moderate effect of the Sp1 polymorphism on bone metabolism, the relationship of the polymorphism with bone phenotypes can easily be skewed, or even masked, by such factors as race, age, estrogen status and nutrition. Hence the predictive power of the Sp1 polymorphism for osteoporosis and fractures is intrinsically limited. Increasing genotype resolution by haplotyping including other polymorphisms, controlling potential heterogeneity by subdividing the study population or by using a family-based study design (Spielman et al. 1993 , Deng et al. 2002a , and identifying more causative polymorphisms using SNP markers and linkage disequilibrium mapping are among some of the alternative approaches to finding the true functional mutations.
ER-gene
The ER-gene is located on chromosome 6q25-27. It comprises eight exons and spans more than 140 kb. Several polymorphisms for the gene have been studied. Among them, the T<C and the A<G in intron 1 and the TA repeat in the promoter region are those most frequently studied. Novel polymorphisms are continuously being identified and tested for association; recent examples include codon 325 (CCC<CCG) (Jurada et al. 2001) , T262C of exon 1 (Ongphiphadhanakul et al. 2001a ), G2014A of exon 8 (Ongphiphadhanakul et al. 2001b) , and G261C of exon 1 (Langdahl et al. 2000b) .
The TA repeat polymorphism is located within the promoter region 1174 bp upstream from exon 1. This polymorphism was speculated to affect bone mass by changing the production or stability of mRNA, resulting in changes in ER number. The hypothesis has yet to be confirmed by functional studies.The association of the polymorphism with BMD was first reported in a study on 144 postmenopausal Japanese women (Sano et al. 1995) . The allele C, having 12 dinucleotide repeats of TA, was found to be associated with lower spine and total body BMD and greater concentrations of markers of bone turnover, including serum osteocalcin, urinary pyridinoline and deoxypyridinoline. The finding was supported by another study that identified the effect of the TA polymorphism on total body calcium (Sowers et al. 1999) . Three more recent studies also confirmed the correlation of the TA repeat number with BMD values in North European (Langdahl et al. 2000b) , Mediterranean (Becherini et al. 2000) and Southern Chinese (Chen et al. 2001b) populations. In the earlier two studies (Becherini et al. 2000 , Langdahl et al. 2000b , the TA repeat number was positively correlated with lumbar or hip BMD -larger numbers of repeats tended to associate with higher BMD values -but the opposite effect was found in the Chinese population (Chen et al. 2001b ). Correspondingly, a high risk for fracture or osteoporosis was conferred by lowrange repeats (11-18) in the European populations (Becherini et al. 2000 , Langdahl et al. 2000b ) and a high number of repeats (TA d20) in the Chinese population (Chen et al. 2001b) .
Two polymorphisms, T<C and A<G, in the first intron have also been extensively studied. They are located respectively 400 bp and 350 bp upstream of exon 2. The functional basis for the influence of the two intronic polymorphisms, defined as PvuII and XbaI, on bone mass variation remains unclear. A possible explanation is that the two polymorphisms may be associated with bone phenotypes via their strong linkage disequilibrium with nearby functional loci, such as the TA repeat in the promoter region, the insulin-like growth factor I gene (IGF-I), and the PTH-related peptide gene (PTHR).
Association of the PvuII and the XbaI polymorphisms with BMD has been detected in many studies (Table 2 ). In general, the XX and pp genotypes (or the X and p alleles) were associated with greater BMD as compared with the xx and PP genotypes (or the x and P alleles) (Kobayashi et al. 1996 , 2002 , Mizunuma et al. 1997 , Willing et al. 1998 , Albagha et al. 2001 . The opposite effect was found in Thai and Korean women, Thai men and Finnish prepubertal girls (Ongphiphadhanakul et al. 1998a , Kim et al. 2001 , Suuriniemi et al. 2002 . A large-scale metaanalysis of 30 studies confirmed both the significance and the direction (XX>other genotypes) of the effect of the XbaI polymorphism on BMD of the total body, femoral neck and lumbar spine (Ioannidis et al. 2002) . However, the meta-analysis could not establish an association between the PvuII polymorphism and BMD.
Notably, two independent Japanese studies found that the individuals with greater bone mass (with the XX and the pp genotypes) also had greater bone turnover and significant bone loss, suggesting that the BMD differentiation between the XbaI or PvuII genotypes tends to decrease with age and disappear eventually through the late postmenopausal period, if there is no intervention. This may help explain why most of the inconsistent results concerning ER-gene polymorphisms came from studies on PvuII and XbaI polymorphisms (Table 3) , as exemplified by studies in 426 Italian postmenopausal women and in 248 Korean postmenopausal women (Han et al. 1997 . Potentially, it may also undermine the value of these two polymorphisms as predictive factors for osteoporosis and fractures.
Other genetic polymorphisms
Since the recognition of the VDR gene polymorphism as one of the important parameters predictive of bone variables, the candidate-gene approach has become the mainstay of the methodology for genetic study of osteoporosis. A host of novel polymorphisms have been identified and related to variation in bone mass and risk for osteoporotic fractures (Table 1) . Most of the polymorphisms are from the genes encoding the important pathways of bone and mineral homeostasis and metabolism. Representatives of these genes include those for transforming growth factor-1 (TGF-1), interleukin-6 (IL-6), IGF-I, calcitonin (CT), calcitonin receptor (CTR) and interleukin-1 receptor antagonist (IL-1ra) ( Table 2) .
TGF-1 has been implicated as a potential mediator coupling bone resorption and formation. The TGF-1 gene has seven exons, of which exons 5-7 encode the active TGF-1. Several polymorphisms of the gene have been studied. In one study of a large sample involving 1706 female dizygotic twins, the T<C polymorphism of intron 5 was associated with femoral neck BMD (Keen et al. 2001) . A study on the 509C<T polymorphism in 625 postmenopausal Japanese women detected its relationship with lumbar spine and total body BMD (Yamada et al. 2001) . Two independent studies of the T<C polymorphism of the signal sequence region yielded different results in terms of the effect of the polymorphism on BMD. A study in a Japanese population identified that the CC genotype was associated with greater BMD and lower frequency of vertebral fracture as compared with the TT genotype , but another one, in a German population, detected that the TT genotype instead was the one associated with greater BMD and less bone loss (Hinke et al. 2001) . Two other polymorphisms, the 713-8 delC and the T<C of exon 1, were also related to BMD, bone turnover, bone loss and response to vitamin D and HRT (Langdahl et al. 1997 , Bertoldo et al. 2000 .
IL-6, as a pleiotropic cytokine, has important effects on osteoclast differentiation and function. It was found to mediate estrogen-deficiency-related bone loss in rodents (Manolagans & Jilka 1995) and its expression was upregulated in bone tissue from osteoporotic patients (Ralston 1994) . A few studies have demonstrated the relationship of several polymorphisms of the IL-6 gene with bone phenotypes, including the variable number tandem repeat (VNTR) polymorphism in the 3 flank region of the gene (Murray et al. 1997) , the CA repeat polymorphism (Tsukamoto et al. 1999) , the BsrBI endonuclease C/G polymorphism at (nt) 634 of the promoter region (Ota et al. 2001) , and the 174 G<C polymorphism (Ferrari et al. 2001) . The latter polymorphism was also associated with bone resorption (Ferrari et al. 2001) , consistent with the osteoclast-dependent regulatory mechanism of IL-6. A functional study of the polymorphism using transfected Hela cells revealed significantly lower expression of IL-6 for the 174 C than for the 174 G construct (Fishman et al. 1998) . That difference in expression between the two alleles persisted upon stimulation of proinflammatory mediators such as IL-1. In addition, the allele C was also found to be associated with lower plasma concentrations of IL-6 in 102 healthy individuals (Fishman et al. 1998) . It is speculated that transcriptional modulation by this polymorphism results from its potential influence on the binding of the glucocorticoid receptor to a nearby region of DNA (Fishman et al. 1998) . It is also possible that the G<C change at 174 creates a potential binding site for the transcription factor nuclear factor-1 (Liu et al. 1997 , Fishman et al. 1998 . These results implicated the 174 G/C polymorphism as the key factor regulating IL-6-mediated inflammatory processes, which are important in the pathogenesis of diseases such as osteoporosis, arthritis and atherosclerosis. The association of the BsrBI polymorphism with BMD (Ota et al. 2001) could not be replicated in a sample of Chinese nuclear families using the transmission disequilibrium test approach (SF Lei IGF-I is produced by osteoblasts and stimulates skeletal growth through its regulation of cell proliferation, differentiation, DNA synthesis, and collagen and non-collagen protein (Canalis 1980 , Mohan & Baylink 1991 , Canalis et al. 1998 , Hock et al. 1998 . It also functions as a mediator of a series of hormones involved in bone metabolism, such as growth hormone, estrogen and PTH (Gray et al. 1989 , McCarthy et al. 1989 , Ernst & Rodan 1991 , Inzucchi & Robbins 1994 , Watson et al. 1995 . A CA repeat polymorphism upstream of the transcriptional initiation site of the gene has been investigated in several studies (Miyao et al. 1998 , Rosen & Donahue 1998 , Kim et al. 2002c . Associations of the polymorphism with both BMD and serum IGF-I concentrations were identified. As serum IGF-I concentrations were correlated with bone mass in both inbred strains of mice (Beamer et al. 1996 ) and humans (Kurland et al. 1997 (Kurland et al. , 1998 and corresponded to the skeletal content of IGF-I (Beamer et al. 1996 , the difference in BMD between IGF-I genotypes may be mediated via variations in serum IGF-I. However, the causative relationship between serum IGF-I and bone mass requires further investigation, as serum IGF binding protein-5 was also found to be positively associated with femoral neck BMD in females (Karasik et al. 2002c) .
Calcitonin is a polypeptide hormone secreted by parafollicular cells of the thyroid gland. It inhibits osteoclastic bone resorption and stimulates urinary calcium excretion. The human CTR belongs to a family of G-proteincoupled receptors with seven spanning domains. Polymorphisms of both the CT and the CTR genes were studied for their relationship with bone mass. In a study in 663 postmenopausal and 52 perimenopausal Italian women, the Alul restriction enzyme polymorphism of the CTR gene was associated with spine BMD, with greater effect in the younger subset (Braga et al. 2000) , suggesting that the polymorphism may have more influence on the peak bone mass than on age-related bone loss. Another two polymorphisms of the CTR gene, the TaqI polymorphism and the T<C polymorphism, were also found to be related to lumbar and femoral neck BMD , Taboulet et al. 1998 . The CA repeat polymorphism of the CT gene was correlated with lumbar BMD in a group of Japanese postmenopausal women, with the 10-repeat allele being associated with lower BMD values .
IL-1 induces bone resportion by activating osteoclasts via osteoblasts and by inhibiting apoptosis of osteoclasts. IL-1ra competes with both IL-1 and IL-1 , the two isoforms of IL-1, for binding with IL-1 receptors without agonist effects. Estrogen-mediated production of IL-1 and IL-1ra represents an important mechanism of postmenopausal bone loss (Pacifici et al. 1998 ). The human IL-1ra gene maps to chromosome 2q13-14 and consists of four exons (Lennard et al. 1992) . A VNTR of 86 bp repeats within intron 2 of the gene was tested for association with bone variables in several studies. Significant association of the VNTR polymorphism with rates of change in spinal bone mass, spine bone loss (Keen et al. 1998) , and lumbar and hip BMD (Langdahl et al. 2000c , Fontova et al. 2002 was identified.
The polymorphisms of other genes related to bone metabolism also have been extensively investigated (Table  2) . A microsatellite marker, D1S3737, of the osteocalcin gene was studied in 1366 non-identical twin sisters (Andrew et al. 2002) . Allele 10 of the marker was found to be negatively associated with BMD, velocity of ultrasound and broadband ultrasound attenuation using a multivariate model-fitting approach. Another polymorphism of the gene, the HindIII polymorphism, was related to humerus BMD in adolescent females; those with the H allele had significantly lower BMD than those without the allele (Gustavsson et al. 2000) . The BstBI polymorphism of the PTH gene was associated with BMD and bone turnover markers in 383 postmenopausal Japanese women . It was also able to influence such important indices of bone geometry as metacarpal diameter, crosssectional cortical area and age-related decrease in radial cortical area (Gong et al. 1999) .
A series of genes have been newly recognized as related to variation in BMD (Tables 1 and 2) (Dickson et al. 1994 , Huizenga et al. 1998 , Tsuji et al. 1998 , Zmuda et al. 1998 , Ogawa et al. 1999 , Sowers et al. 1999 , Salamone et al. 2000 , Spotila et al. 2000 , Tsukamoto et al. 2000a ,b, Urano et al. 2000 , Masi et al. 2001 , Ogata et al. 2001 , Albagha et al. 2002 , Arko et al. 2002 , Eckstein et al. 2002 , Fontova et al. 2002 , Gennari et al. 2002 , Karasik et al. 2002d , Kawano et al. 2002 , Minagawa et al. 2002 , Prince et al. 2002 , Suuriniemi et al. 2002 , Vaughan et al. 2002 , Wynne et al. 2002 . For most of these genes, these were the first reports of an association with BMD and there is a need to repeat the findings in independent studies. There has been preliminary confirmation of the relevance of several genes to variation in BMD. Two studies on the ER-gene both detected association of the CA repeat polymorphism with BMD, one at the lumbar spine (Ogawa et al. 2000) and another at Ward's triangle (Karasik et al. 2002d ); a larger number of repeats tended to be associated with greater BMD in both studies. The TTTA repeat polymorphism of the CYP19 gene was studied in both 1337 elderly women (Prince et al. 2002) and 300 elderly men (Gennari et al. 2002) . The first study demonstrated that reduced hip BMD was associated with high TTTA repeat number (>12), but the second study revealed a greater rate of bone loss in individuals with low numbers of repeats (<9) than in those with high repeat rates (>9), implying potentially different effects of the polymorphism between the sexes. Relationships between -2-HS glycoprotein gene polymorphism and bone-related phenotypes have been detected, namely for lumbar/femoral BMD (Dickson et al. 1994 ) and for calcaneal broadband ultrasound attenuation (Zmuda et al. 1998) . More consistent results were achieved for the studies of apolipoprotein E gene polymorphism. Shiraki et al. (1997) reported the presence of the ApoE4 allele to be associated with lower lumbar spine BMD and higher bone turnover. Subsequently, Salamone et al. (2000) detected significantly greater annual bone loss in the individuals with the ApoE4 allele, providing evidence in support of the earlier findings.
Gene gene and gene non-genetic factor interactions
Gene gene or gene non-genetic factor interactions have been identified in many studies, reflecting multifactorial determination of bone mass and the complexities of the genetic basis underlying BMD (Table 5) . Gene gene interaction involving the VDR, the ER-, and the COLIA1 genes was implied in a few studies. The genotype PP (ER-PvuII) bb (VDR BsmI) was associated with greater BMD values than PP BB in white American women (Willing et al. 1998) . In 1004 postmenopausal women (Uitterlinden et al. 2001) , the fracture risk was found to be dependent on the baT haplotype of the VDR gene in only the COL1A1 GT and TT, but not the GG genotype group. Another study in Italian women showed that the interaction could exist not only between different genes, but also among different loci of the same gene; the two haplotype groups, AABBtt and aabbTT, formed by the combination of the three polymorphism sites of the VDR gene , differed significantly with respect to lumbar BMD. Such intragene/inter-locus interaction has also been identified in prepubertal white females (Ferrari et al. 1998b ) and young adult males (Ferrari et al. 1999) .
Non-genetic factors, including age (Riggs et al. 1995 , Ferrari et al. 1998a , Uitterlinden et al. 1998 , Drummond et al. 2002 , race (Fleet et al. 1995 , Harris et al. 1997 , calcium intake (Kiel et al. 1997 , Ferrari et al. 1998a , Rubin et al. 1999 , Brown et al. 2001 , vitamin D supplementation (Graafmans et al. 1997) , HRT (Giguère et al. 2000 , Salamone et al. 2000 , Salmen et al. 2000 , years since menopause (Gennari et al. 1999) , caffeine intake (Rapuri et al. 2001) , birthweight (Dennison et al. 2001) , BMI (Gennari et al. 2002 , testosterone concentrations (Gennari et al. 2002) and exercise (Rubin et al. 1999 ) may also interact with genetic factors in determination of bone mass.
Because of its importance for gene-environment interaction in bone metabolism, the effect of calcium or vitamin D intake on the accrual or retention of BMD has been analyzed in several independent studies (Krall et al. 1995 , Graafmans et al. 1997 , Kiel et al. 1997 , Ferrari et al. 1998a , Brown et al. 2001 . The effect was manifested clearly only in those with the VDR gene Bb, and possibly the BB, genotypes, but not those with the bb genotype (Ferrari et al. 1998a ). This finding is supportive of that by Graafmans et al. (1997) , who also reported that an increase in BMD as a result of vitamin D supplementation was greater in BB and Bb individuals than in bb individuals. In contrast, the study by Kiel et al. (1997) showed that only the bb, rather the BB and Bb, individuals exhibited an increase in BMD in response to calcium intake. This inconsistency of genotype in individuals who benefit most from nutritional supplementation is probably attributable to their age differences, as participants in the study by Kiel et al. (1997) were in the age range 18-69 years, much older than the prepubertal participants in the study by Ferrari et al. (1998a) . The effect of calcium intake in curbing postmenopausal bone loss may also vary for different sites. According to Krall et al. (1995) , only the femoral neck bone loss in BB individuals could be alleviated significantly by calcium supplementation.
The above inconsistency underscores the importance of another factor, age, for its pivotal role in interacting with other factors in the determination of BMD. Riggs et al. (1995) studied 139 normal and 43 osteoporotic women, and found that the VDR genotypic difference with respect to BMD tended to blur with advancing age and eventually disappeared by the age of 70 years, implying erosion of genotypic differentiation of BMD by environmental effects accumulated over time. This is generally confirmed by the findings of another study in which BMD was associated with VDR polymorphisms only before puberty (Ferrari et al. 1998a) , but is contradicted by those of a study in 1778 postmenopausal Dutch women, in whom BMD genotypic differentiation was accentuated by advancing age (Uitterlinden et al. 1998) . A study by Drummond et al. (2002) demonstrated the complexity of the interplay between age and genetic factors. In that study, bone loss was found to be greater for the VDR FF and the osteoprotegerin gene (OPG) CC genotype than for the VDR Ff/ff and OPG GC/G genotype in individuals older than 60 years. As the VDR FF genotype was generally associated with greater BMD and the OPG C allele was associated with lower BMD (Wynne et al. 2002) , it is to be expected that, with advancing age, BMD differentiation would tend to decrease in terms of VDR genotype and would tend to increase in terms of the OPG genotype. The overall effect of gene-age interaction on BMD of an individual with both FF and CC genotype would thus depend on these two opposite trends of age-related change in BMD.
Gene-age interaction has also been suggested to influence weight, such that individuals with the ER-PP genotype tended to gain weight and those with the Pp and pp genotypes lost weight with advancing age (Deng et al. 2000b) . As weight and bone mass are highly correlated, the finding implies that the effect of gene-age interaction on BMD might be mediated through weight. In addition, weight -or probably height -itself may also potentially interact with the VDR polymorphism to influence BMD variation. Vandevyver et al. (1997) discovered, in a group of elderly women, that BMD differentiation among the BsmI genotypes could be detected only in non-obese women with BMI<30 kg/m 2 . Similarly, it was also reported that, among 332 postmenopausal Danish women, an association of the f and b alleles of the VDR gene with lower BMD could be found only in those with BMI less than 25 kg/m 2 . The findings are consistent with the conclusion of Deng et al. (1999) that covariates, such as weight and height, may obscure the associations of the VDR and ER-genotypes with BMD.
HRT is another important environment factor that modulates genetic effects on bone. In a study by Deng et al. (1998) , HRT tended to have differential effects for different VDR genotypes. In groups with the BB and Bb genotypes, HRT increased the distal radius BMD, but it tended to have the opposite effect on distal radius BMD in bb individuals. A study on 322 early postmenopausal women showed that differences in BMD that were related to the ER-genotype were eliminated by long-term HRT (Salmen et al. 2000) . HRT could also remove the difference in bone loss between the individuals with the ApoE4 allele and those without it (Salamone et al. 2000) . Another study identified individuals with the VDR bb/ ER-PP genotype as a group who might benefit most from long-term HRT because, in that study, only those with the genotype bb-PP had an increased heel stiffness index in response to long-term HRT (Giguère et al. 2000) .
Studies on race (white compared with African American) VDR genotype interaction have not yielded positive effects (Fleet et al. 1995 , Harris et al. 1997 ). This may be unexpected, given that the association between the VDR polymorphism and BMD is much more often detected in white Americans than in African Americans (Zmuda et al. 1997 (Zmuda et al. , 1999a .
Implications of monogenic bone diseases/traits and transgenic/knockout animal models for association studies
A series of candidate genes have been identified through the study of monogenic bone diseases/traits. Likewise, by means of knockout and transgenic animal models, many well-known or novel genes have been found to be accountable for abnormal bone phenotypes. Studies on monogenic bone diseases and genetically manipulated animals can effectively complement association studies in elucidating the genetic factors of osteoporosis. They provide biologically relevant new candidate genes of osteoporosis for association studies to be tested in general populations. They can also help isolate and highlight the functions of a particular candidate gene, thus providing further evidence supporting the gene's relevance to variations in bone mass.
A salient example is the TGF-1 gene. Associated with lumbar spine BMD and markers of bone turnover in postmenopausal women, the gene has also been implicated in the pathogenesis of Camurati-Engelmann disease (Kinoshita et al. 2000) , an autosomal dominant disease characterized by progressive hyperosteosis and sclerosis of the diaphyses of the long bones. The importance of the gene to bone mass regulation was further validated in TGF-1-knockout mice. Lack of the gene in these mice resulted in a significant decrease in bone mineral content and elasticity (Geiser et al. 1998) . Recently, studies on three monogenic traits -autosomal recessive osteoporosispseudoglioma (Gong et al. 2001) , autosomal dominant high bone mass (Johnson et al. 2002 , Little et al. 2002 , and autosomal recessive osteopetrosis (Heaney et al. 1998 ) -have brought to light another gene, the low-density lipoprotein receptor-related protein 5 gene (LRP-5) as a potential candidate gene for osteoporosis. The first two traits were proved to result from different mutations of the LRP-5 gene (Gong et al. 2001 , Little et al. 2002 , and the last was linked to the genomic region, 11q12-13 (Heaney et al. 1998) , which contains the gene. To confirm the significance of the gene for bone mass variation in the normal population, several independent studies were performed testing linkage of the genomic region, 11q12-13, with BMD. A sib-pair study with 374 sibships reported that a maximum logarithm of odds (LOD) score of 3·50 was achieved in this region for linkage to femoral neck BMD (Koller et al. 1998) . However, a subsequent study by the same group with an expanded sample size of 595 sib pairs demonstrated a much reduced LOD score (<2·2) for linkage of this region to BMD . Moreover, the findings of a study by Deng et al. (2001a) did not suggest any significance of this region, and neither did several later large genome-wide linkage studies (Mitchell et al. 2001 , Karasik et al. 2002a , Wilson et al. 2003 .
For more detailed illustration of monogenic bone diseases and transgenic/knockout animal models for genetic studies of osteoporosis, the reader is referred to the reviews by Ralston (2002) and Peacock et al. (2002b) .
Linkage studies
Linkage studies test whether a phenotypic locus is transmitted with genetic markers of known chromosomal Continued position.The linkage approach does not rely on the linkage disequilibrium among genes or markers in adjacent genomic regions, and therefore it can be used to search for any genomic region that contributes relatively large variation in complex traits, without any prior knowledge. In contrast to the population association approach, the linkage approach is robust with respect to population admixture/ stratification. However, genomic regions detected by linkage studies are generally large (30 cM), and are thus not suitable for physical mapping; fine-mapping techniques are therefore needed to narrow down a QTL to a small region in order eventually to identify a specific gene (Deng & Chen 2000a , Deng et al. 2000a . The linkage approach has been successfully used to locate gene(s) underlying Mendelian inherited genetic traits, but its application to complex traits can be complicated (Lander & Schork 1994) . In this case, it is necessary to screen or genotype (or both) very large samples (Risch & Merikangas 1996 , Allison 1997 , Xiong et al. 1998 , or the power to detect linkage would be limited.
Linkage studies in humans
In recent years, the linkage approach has been applied to the search for genes associated with osteoporosis. Table 6 presents a summary of the loci showing evidence of linkage with BMD and other important risk determinants of osteoporosis. These results are derived from either whole-genome linkage scans or candidate loci searches.
Whole-genome linkage scans Generally, genomewide linkage scans are conducted by using panels of microsatellite makers spaced uniformly throughout the entire human genome to identify QTLs affecting the traits. Sampling strategy involves gathering a large number of related individuals assumed to be segregated for genes that influence the traits. To date, genome-wide linkage scans are relatively rare in the field of bone genetics. Ten studies on osteoporosis-related phenotypes have been published. Among these, six focused on BMD (Devoto et al. 1998 , Niu et al. 1999 , Karasik et al. 2002a , Deng et al. 2002c , Wilson et al. 2003 , two on bone size (Koller et al. 2001 , Deng et al. 2002b , one on serum osteocalcin concentration (Mitchell et al. 2000) and one on quantitative ultrasound of the calcaneus bone (Karasik et al. 2002b) . Abstracts for several other linkage analyses have also been published (Mitchell et al. 2001 , Econs et al. 2002 , Huang et al. 2002 , Koller et al. 2002 , Peacock et al. 2002a , Wilson et al. 2003 , some with the purpose of confirming preliminary findings. General information on sampling strategies and molecular markers utilized in the eight full publications to date on whole-genome linkage studies are outlined and compared in Table 7 . We also briefly review these studies according to study phenotype. BGP, osteocalcin; BMP-3, bone morphogenic protein-3; BMP-4, bone morphogenic protein-4; BMP-6, bone morphogenic protein-6; CALM2, calmodulin 2; CHAD, chondroadherin; CDMP1, cartilage-derived morphogenetic protein 1; COL1A1, type I collagen 1; COL2A1, type II collagen 1; COL4A1, type IV collagen 1; COL4A2, type IV collagen 2; COL5A1, collagen type V 1; COL6A1; collagen type VI 1; COL6A2, collagen type VI 2; COL6A3, collagen type VI 3; COL8A1, type VIII collagen 1; COMP, cartilage oligomeric matrix protein; CRTL1, cartilage linking protein 1; EGF, epidermal growth factor; ER-, estrogen receptor-; FGFR2, fibroblast growth factor 2; FGFR3, fibroblast growth factor 3; HOX: homeobox genes; IGF-I, insulin-like growth factor I; IGF-II, insulin-like growth factor II; IL-1 , Interleukin-1 ; IL-4, interleukin-4; IL-6, interleukin-6; IL-6R, interleukin-6 receptor; LRP5, low density lipoprotein receptor-related protein 5; MTHFR, methylenetetrahydrofolate reductase; ON, osteonectin; PDGFRB, platelet-derived growth factor receptor-; PLOD, lysyl hydroxylase; POMC, pro-opiomelanocortin; PRTN3, proteinase 3; PTHR1, PTH receptor type 1; STK, serine/threonine kinase; TBX2, T-box 2; TNF-, tumor necrosis factor ; TNFRSF1B, tumor necrosis factor receptor subfamily 1B; TNFRSF11B, osteoprotegerin; VDR, vitamin D receptor. BMD The first genome-wide study for genomic loci involved in bone density was that by Devoto et al. (1998) , in which a total of 149 individuals from seven large pedigrees (74 sib pairs) with low BMD were genotyped for 330 markers. The maximum LOD score obtained in parametric analyses was 2·08 for the marker CD3D at chromosome 11q for femoral neck BMD. Non-parametric analyses suggested linkage at chromosome 1p36 for femoral neck BMD (Z max =3·51 for D1S4450), 2p23-24 for spine BMD (Z max =2·07 for D2S149), and 4 qter for femoral neck BMD (Z max =2·95 for D4S1539 and Z max =2·48 for D4S1554). Niu et al. (1999) scanned the entire autosomal genome by genotyping 367 polymorphic markers for 218 individuals from 96 Chinese nuclear families (including 153 sib pairs). A genomic region covering 2p21.1-24 was linked to both proximal and distal forearm BMD (LOD=2·15 and 2·14 for proximal and distal forearm BMD respectively), and 13q34 was linked to distal forearm BMD with a multipoint LOD score of 1·67. Koller et al. (2000) performed a genome scan for BMD at the lumbar spine, trochanter, femoral neck and Ward's triangle using 429 healthy premenopausal white sister pairs. In their study, chromosomal regions showing LOD scores greater than 1·85 were further replicated in an expanded sample with 464 white and 131 AfricanAmerican sister pairs. The highest LOD score of 3·86 was reached at chromosome 1q2-23 with lumbar spine BMD. Evidence of suggestive linkage was also found at 5q33-35 (LOD=2·23) and 11q12-13 (LOD=2·16) with femoral neck BMD, at 6p11-12 (LOD=2·13) with lumbar spine BMD. Deng et al. (2002b) genotyped 380 microsatellite markers throughout the entire human genome for 635 white individuals from 59 extended pedigrees identified via probands with extremely low BMD values. This study contained more than 11 000 relative pairs (including 1249 sib pairs) informative for linkage analyses. For spine BMD, four putative genomic regions (4q31, 7p22, 12q24 and 13q33-34) were identified, with a greatest multipoint LOD score of 3·08 at 4q31. For hip BMD, the evidence of linkage was detected at the genomic regions 10q26, 12q13 and 17p11, with a maximum multipoint LOD score of 2·29 at 10q26. Suggestive linkage to wrist BMD was also found at genomic regions 3p26, 4q32, 9p22-24 and 17p13. Another genome-wide scan was performed in a randomly ascertained set of 330 healthy white pedigrees from the population-based Framingham Study (Karasik et al. 2002a) . The investigators reported suggestive twopoint linkage of BMD at the femoral neck to 6p21.2 (LOD=2·93), linkage of trochanteric BMD to 21q22.2 (LOD=2·34), and possible linkage of lumbar spine BMD to 12q24.2 and 6p21.2. In the multipoint analysis, strong evidence of linkage was shown with trochanteric BMD at 21 qter (D21S1446) (LOD=3·14). Other regions of possible linkage (LOD>2·2) were at 21q22.2 with trochanteric BMD, 8q24 with Ward's area, and 14q31 with lumbar spine BMD. Wilson et al. (2003) performed independent genome-wide screens on two complementary cohorts: unselected non-identical twin pairs (1094) and highly selected extremely discordant or concordant (EDAC) sib pairs (254 pedigrees). The evidence of linkage in the unselected twins (spine BMD, LOD=2·7) and the EDAC pedigrees (spine BMD, LOD=2·1) was observed at genomic region 3p21. Furthermore, suggestive linkage was found in twin cohorts for whole-body BMD (LOD=2·4) at 1p36.
In a study in 898 individuals from 34 MexicanAmerican families, reported at the preliminary stage (Mitchell et al. 2001) , significant linkage was detected at genomic region 4p (LOD=4·05) to BMD at the midpoint radius. Additional evidence of linkage to BMD at the hip (intertrochanteric region) was also observed at the same region (LOD=2·2).
Bone size Koller et al. (2001) genotyped 270 markers for 309 white sister pairs to identify genomic regions underlying normal variation of femoral structure (including seven structure variables). Three chromosomal regions5q, 4q and 17q -were identified as having significant evidence of linkage (LOD>3·6) to at least one femoral structure phenotype. In another study, for a sample of 53 pedigrees that included 1249 sib pairs, Deng et al. (2002b) performed a whole-genome scan using 380 microsatellite markers to identify genomic regions potentially containing QTLs important for variation in bone size (measured by dual-energy X-ray absorptiometry). For variation in wrist (ultra distal) bone size, a LOD score of 3·89 was achieved at D17S787 in two-point linkage analyses and a LOD score of 3·01 was achieved at 17q23 in multipoint analyses. For variation in hip bone size, a LOD score of 1·99 was achieved at D19S226 in two-point analyses, and a LOD score of 2·83 was achieved at 19p13 in multipoint analyses.
Serum osteocalcin concentration Serum osteocalcin concentration has been regarded as a biochemical marker of bone turnover. A genome-wide scan of serum osteocalcin concentration in 429 individuals from 10 pedigrees (Mitchell et al. 2000) revealed significant linkage at genomic region 16q11.1-13 (LOD=3·35), and suggestive linkage on 20q11.1-13.12 (LOD=2·78). Karasik et al. (2002b) conducted a whole-genome scan in 324 white families (1270 measured individuals) from the Framingham Osteoporosis Study to identify genomic regions that may harbor genes influencing variation in calcaneal ultrasound measures (including broadband ultrasound attenuation, speed of sound and quantitative ultrasound index). Evidence of linkage was detected on chromosomes 1p36.3 and 5p15.2.
Quantitative ultrasound
Linkage studies on candidate loci Some linkage studies were performed in candidate genomic loci or targeted chromosomal regions. In a sib-pair linkage study of 23 candidate genes, Duncan et al. (1999) genotyped 64 microsatellite markers in a sample of 115 probands identified from patients with primary osteoporosis and 499 of their relatives. Suggestive linkage was found between BMD and the PTHR1 gene (LOD>2·7). Suggestive evidence of linkage was also observed with the genes for epidermal growth factor, COLIA1, COLIA2, VDR, ER-, IL-, IL-4 and IL-6. In another study, Ota et al. (1999) tested 192 sibling pairs of adult Japanese women from 136 families for genetic linkage between osteopenia and allelic variants of four candidate genes CaSR, and MGP) . Significant linkage of the IL-6 locus to osteopenia was observed by qualitative methods. Evidence of linkage was also found between low BMD and the IL-6 locus by quantitative methods. In the same study sample, Ota et al. (2000) observed linkage between osteoporosis and osteopenia and allelic variants at the tumor necrosis factor-(TNF-) locus. In a sample of 542 healthy premenopausal sibling pairs (418 white and 124 AfricanAmerican pairs), Takacs et al. (1999) did not find evidence of linkage between BMD and the IGF-I gene polymorphism for spine or hip BMD. In a similar study, Takacs et al. (2000) found no evidence for either linkage or association between the IL-6 gene locus and BMD at the spine or femoral neck. Deng et al. (2002a) simultaneously tested linkage, association, or both (via the transmission disequilibrium test) for three candidate genes (VDR, BGP and PTH) as putative QTLs underlying spine or hip BMD variation. Their data support the VDR gene as a QTL underlying spine BMD variation and BGP as a QTL underlying hip or spine BMD variation. Using similar statistical methods, Andrew et al. (2002) tested linkage and association for BMD and heel ultrasound measurements near the osteocalcin gene in female dizygotic twins. Strong evidence for pleiotropic linkage was found for broadband ultrasound attenuation and BMD in postmenopausal women.
Human chromosomal region 11q12-13 has been of great interest for many investigators in the bone genetics field during the past few years. Three distinct Mendelian inherited traits that are BMD related, including osteoporosis-pseudoglioma (Gong et al. 1996) , autosomal recessive osteopetrosis (Heaney et al. 1997) , and an autosomal dominant trait characterized by high bone mass (HBM) (Johnson et al. 1997) , have been linked to this region. Little et al. (2002) refined this region with the expanded HBM pedigrees. A systematic search for mutations that segregated with the HBM phenotype revealed that a mutation in the LRP-5 gene results in the HBM phenotype. Subsequent studies demonstrated that the LRP5 V171 mutation causes high bone density, with a thickened mandible and torus palatinus, by impairing the action of a normal antagonist of the wingless type (Wnt) pathway and thus increasing Wnt signaling (Boyden et al. 2002) . A study in 374 sib pairs for seven microsatellite markers typed in 11q12-13 (Koller et al. 1998) reported linkage to normal femoral neck BMD variation (LOD=3·50 with marker D11S987). However, a subsequent study with an expanded sample size (595 sib pairs) revealed much reduced signal for linkage, with a LOD score less than 2·2 achieved at D11S987. Deng et al. (2001b) genotyped five markers in this region (27 cM centering on D11S987) for 635 individuals from 53 extended pedigrees (including 1249 sib pairs), but did not find linkage involving BMD at the spine, hip, wrist or total body BMD.
Replications Several genomic regions have been replicated across different studies. The genomic region 2p23-24 linked to spine BMD in white populations (Devoto et al. 1998) overlaps the region 2p21.1-24 revealed by Niu et al. (1999) for both proximal and distal forearm BMD in Chinese sib pairs. A number of candidate genes, such as calmodulin 2 (CALM2), serine/threonine kinase (STK) and pro-opiomelanocortin (POMC) reside in this region. A genome scan of 1097 female UK twin pairs (Wilson et al. 2003) confirmed the presence of QTLs for BMD at 1p36 and 3p21 highlighted by Niu et al. (1999) and Duncan et al. (1999) . Important candidate genes, including TNFR2 and PTHR1, are located at 1p36 and 3p21 respectively. There is also potential evidence for replication on chromosomal region 4q31 and 13q34 in three different studies (Duncan et al. 1999 , Niu et al. 1999 , Deng et al. 2002c . Two candidate genes (COL4A1 and COL4A2) are located at 13q34.
Several groups have made extensive efforts in either independent or expanded samples (partially overlapping with initial samples) to confirm the findings in their initial stage studies. To confirm the QTLs influencing BMD revealed by Deng et al. (2002c ), Huang et al. (2002 conducted a second-stage linkage study with more dense markers within the initial localized regions in expanded pedigrees. Evidence of potential replication (LOD>1·0) was found at several regions, such as 10q26, 7p22, 12q13 and 13q33-34. A study by the same group also replicated a QTL at 17q23 that influenced the variation in wrist bone size revealed by Deng et al. (2002b) . Another group reported replications of their initial-stage results on chromosome 1q for spine BMD (Econs et al. 2002) , on chromosomes 14 and 15 for hip BMD (Peacock et al. 2002a) , and at chromosomes 3 and 9 for femoral structure (Koller et al. 2002) .
Statistical power of current linkage studies for osteoporosis
The disagreement in results between different linkage studies may reflect the complexity of genetic inheritance of osteoporosis. Other possible reasons may lie in the diversity of study designs, sample sizes, ascertainment schemes and statistical analyses used. From the statistical genetics point of view, power issues involving linkage analysis are of critical importance in interpreting the inconsistency across the different studies.
Currently, two basic analytical approaches of modelfree linkage analysis -the sib-pair method (Haseman & Elston 1972 ) and variance components method (Amos 1994 , Almasy & Blangero 1998 ) -are routinely used in osteoporosis gene mapping. The merit of the sib-pair method is its relative simplicity of design and computation, but it is of limited power when the sample size is small or when sibling pairs are ascertained randomly (Risch & Merikangas 1996 , Xiong et al. 1998 . For instance, more than 8000 randomly ascertained sibling pairs are needed in a whole-genome scan to detect a major locus with a heritability as large as 30% (Xiong et al. 1998) . The variance components method may provide a more powerful test, which can be expanded to deal with pedigrees of arbitrary size and complexity (Williams & Blangero 1999) ; generally, the larger and more complex the sample, the more powerful is this method (Williams & Blangero 1999) . Several other factors, such as marker heterozygosity, genotyping error rate and marker density, may also affect the power to detect a QTL. In addition, sampling through extreme probands may improve the linkage power (Risch & Zhang 1995 , Deng & Li 2002 .
We discuss here the potential problems of the inference made in several earlier studies, with the hope of interpreting the linkage findings correctly. In a recent genomewide scan study in 595 white and black sister pairs, Koller et al. (2000) reported several genomic regions that may harbor QTLs affecting BMD; a high LOD score (3·86) was achieved. In the two subsequent extension studies with fewer than 800 sib pairs, the same group replicated several of their major linkage findings (Econs et al. 2002 , Peacock et al. 2002a ). We calculated the statistical power for 595 independent sister pairs and compared it with data from another study (Deng et al. 2002c) in which 53 pedigrees containing 1249 sibling pairs were analyzed. Koller et al. (2002) did not provide the overall heritability (h 2 ) of BMD in their sample; therefore, we set the overall heritability (h 2 ) of BMD as 0·60 (Peacock et al. 2002b) . We assumed the frequency of the allele causing a decrease in BMD to be 0·40, a relatively liberal situation for achieving high statistical power. The power for sib pairs is computed using the program Genetic Power Calculator (Sham et al. 2000 ) (available at http:// statgen.iop.kcl.ac.uk/gpc/). The power of the complex pedigrees (Deng et al. 2002c ) was estimated via simulations by using the program simqtl in SOLAR (Blangero & Almasy 1997 ) (available at http://www.sfbr.org/sfbr/ public/software/solar/). The results showed that, even when the QTL effect was high (h 2 attributable to the QTL is 0·25), and the marker was the QTL (ϑ=0), the power of the study was less than 30% (Fig. 1) . The power decreased dramatically when the distance of marker and the QTL was 5 cM (ϑ=0·05). Compared with sib pairs , the complex pedigrees (Deng et al. 2002c ) had much higher power; nevertheless, it was still insufficient to detect QTLs powerfully when h 2 was less than 30%.
Because of polygenic inheritance, in a whole-genome scan some QTLs may be detected even if the statistical power is low (Deng et al. 2001b) . However, to detect linkage of a specific QTL (e.g. to replicate a previous linkage finding), the statistical power required under a high LOD score should be sufficient. We also calculated the sample sizes required (with 80% statistical power) to detect QTLs at a LOD score of 3·0 with sib pairs. The number of sib pairs required is rather large (from 945 to 10 580) when the QTL effect is intermediate (h 2 attributable to the QTL is between 0·10 and 0·30) ( Table 8 ). The empiric ability to replicate previous whole-genome linkage results (Econs et al. 2002 , Peacock et al. 2002a ) with fewer than 800 sib pairs seems to suggest the existence of a major gene with a h 2 greater than 30%. Only, and even if, with such a dramatic magnitude of h 2 attributable to a single QTL, can we have 80% power to detect it with at least 945 sib pairs. With the existence of such a major gene in humans, some other studies (e.g. Deng et al. 2002c , Karasik et al. 2002a , Wilson et al. 2003 ) might have had a greater power to detect it in similar populations; however, this has not been the case.
The above power analyses suggest that: (1) a high LOD score does not necessarily indicate that the study is more powerful or that the results are more robust than those of other studies; (2) it is inappropriate to use the negative findings of linkage studies that have insufficient power as a gold standard to judge the importance of candidate genes, as these genes may have relatively small or moderate effects on the studied traits; (3) without sufficient statistical power, it will be a challenge to resolve the continuously appearing significant (within individual groups) but yet largely inconsistent (across study groups) results from linkage analyses.
QTL mapping in animals
QTL mapping in animal models provides a complementary tool to identify genes involved in complex human diseases, with a key assumption that major regulatory genes will be shared among different species. The mouse models have been most often used, with a preliminary study also reported in the baboon.
Starting with two completely inbred parental lines, a number of line-cross populations derived from the F1 can be used for QTL mapping. In BMD-related mouse models, the basic idea is to set up experimental crosses of mouse strains with low BMD and high BMD, and then backcross the F1 to one parental line to generate the backcross lines, or to intercross the F1 population to generate the F2 mice with markedly varying BMD. Besides the backcross lines and the F2 mice, other line-cross populations may provide an alternative strategy. For instance, recombinant inbred lines, which can be constructed by taking an F1 line through several rounds of selfing or brother-sister mating, may allow marker-trait associations to be scored in a completely homozygous background and across several environments (Lynch & Walsh 1998) . QTL mapping then can be conducted in experimental crosses with sufficient polymorphic molecular markers spanning the whole genome or candidate loci. Once the chromosomal regions harboring murine QTLs have been identified, the homologous human chromosomal regions may be revealed by human-mouse conserved synteny maps. We summarize the current findings of QTLs important in mice and the corresponding human homologous regions in Table 9 . The study strategies of the available whole-genome QTL mapping for BMD-related traits in mice are reviewed in Table 10 . Using 24 recombinant inbred BXD strains, derived from a cross between progenitors of C57BL/6 (with a low BMD) and DBA/2 (with a high BMD), Klein et al. (1998) detected 10 chromosomal regions linked to peak BMD development in female mice. In the subsequent study with three additional independent populations derived from the same progenitors, Klein et al. (2001) confirmed their findings on chromosomes 1, 2, 4 and 11. Shimizu et al. (1999) reported a whole-genome scan for QTLs underlying peak BMD variation with the F2 intercrosses of SAMP6 (with a low BMD) and SAMP2 (with a high BMD). Significant evidence of linkage was identified on chromosomes 11 (LOD=10·8) and 13 (LOD=5·8). In a further study, Shimizu et al. (2001) elucidated the effects of the chromosome 13 locus (Pbd2) on peak BMD using SAM strains and a congenic strain, P6.P2-Pbd2 b . Their data confirmed the existence of a Pbd2 locus that regulates peak BMD in the SAM strains. Benes et al. (2000) analyzed crosses between SAM6 (with a low BMD) and either AKR/J or SAM1 (with a high BMD). They detected multiple QTLs regulating spine BMD on chromosomes 2, 7, 11, 13 and 16, some of which coincide with those identified in a previous study (Klein et al. 1998) . Beamer et al. (1999) performed a genome scan in a cohort of F2 mice derived from intercross mating of (C57BL/6Jx CAST/EiJ) F1 parents and identified four QTLs (Bmd1, Bmd2, Bmd3 and Bmd4). In another study, Beamer et al. (2001) analyzed 986 B6C3 F2 female inbred strains derived from C57BL/6J (B6) and C3H/HeJ (C3) mice. A total of 10 chromosomes (1, 2, 4, 6, 11, 12, 13, 14, 16 and 18) carrying QTLs for femur BMD and seven chromosomes (1, 4, 7, 9, 11, 14 and 18) carrying QTLs for vertebral BMD were found. Drake et al. (2001b) investigated the phenotypic and genetic relationships among BMD-related traits and those of adipose tissue and plasma lipids in mice with diet-induced atherosclerosis. Six loci that linked to bone-related traits on chromosomes 2, 3, 6, 7 and 15 were identified, three of which coincided with the loci linked to adipose tissue and plasma high-density lipoprotein. In another study, Drake et al. (2001a) conducted a genome screen with 16-month-old female F2 progeny of a C57BL/6J DBA/2J intercross for measures of femur length and width. Evidence of linkage was found on proximal chromosome 3 (LOD=6·1) and chromosome 14 for femur length. A QTL affecting width of the diaphysis was found on chromosome 7 (LOD=6·8). Suggestive linkage for width at the intertrochanteric region was found on chromosomes 6 and 19. Zhang et al. (2002) presented a preliminary report of a locus on chromosome 4 (LOD=18·4) that influenced BMD in BXD mice (C57BL/6 DBA/2 recombinant strains), in addition to a locus on chromosome 19 (LOD=13·3) that influenced osteoclastogenesis. The only available study using the baboon model revealed a chromosomal region (homologous to human 11q12) linked to BMD variation ).
Summary
Understanding of osteoporosis has evolved within the past decade, thanks to extensive molecular genetics research. With the important findings available as summarized in this article, the genetic basis of osteoporosis becomes more finely delineated, as witnessed by the identification of a list of candidate genes, genomic regions and interactions between genes and environment that underlie variation in bone-related traits. However, the majority of these findings perhaps remain inconclusive pending further investigation, given that a large number of conflicting or contradictory discoveries persist for which the reasons are unidentified. Reflecting the complicated inheritance patterns of osteoporosis as a complex disease, the inconsistencies call for new approaches and strategies that have both sensitivity and robustness to accommodate confounding effects from various sources, including genetic heterogeneity, population admixture and gene-gene or geneenvironment interactions, to name but a few. Only on the Continued basis of such sound methodologies can the controversies be resolved and real breakthroughs be made in the search for osteoporosis genes. 
